Abstract: Use of an inhibitor of the renin-angiotensin system or a pharmaceutically acceptable derivative thereof, optionally together with another antihypertensive, a cholesterol lowering agent, a diuretic or aspirin, in the manufacture of a medicament for the prevention of cardiovascular events; a method of preventing cardiovascular events comprising administering to a patient in need of such prevention an effective amount of an inhibitor of the renin angiotensin system or a pharmaceutically acceptable derivative thereof, optionally together with another antihypertensive, a cholesterol lowering agent, a diuretic or aspirin; and a combination product containing an an inhibitor of the renin-angiotensin system or a pharmaceutically acceptable derivative thereof and a cholesterol lowering agent.

Abstract: This invention provides for the treatment of inflammatory, cancer and thrombotic disorders through the administration, in combination, of a COX2 inhibitor, low dose aspirin, and antioxidant flavanoids, flavonoids or isoflavones and at least one of these combinations will be given in a subtherapeutic amount for improved anti-inflammatory, anti-cancer, and anti-thrombotic efficacy and safety.

Abstract: A method for accelerating the process of removing ethanol from the blood through the use of certain additives that accelerate the metabolic oxidation of ethanol, and others which in addition act as catalysts or “pseudo” enzymes for the oxidation. These additives include multivalent transition metal ions, as well as complexes thereof, and NAD+ which enhance the oxidation reaction. The method described can act as a sobriety inducer and/or as an effective palliative for the unpleasant effects of overuse of ethanol.

Abstract: The invention relates generally to an aspirin formulation which may comprise additional vitamins, minerals, herbs and supplements and methods for using the same for maintaining cardiovascular health. The aspirin formulation may comprise supplements such as vitamin B6, vitamin B12, folic acid, arginine and garlic. The invention also encompasses methods for maintaining healthy blood pressure and cholesterol levels with the aspirin formulation described herein.

Abstract: The invention relates generally to an aspirin formulation which may comprise additional vitamins, minerals, herbs and supplements and methods for using the same for maintaining cardiovascular health. The aspirin formulation may comprise supplements such as vitamin B6, vitamin B12, folic acid, arginine and garlic. The invention also encompasses methods for maintaining healthy blood pressure and cholesterol levels with the aspirin formulation described herein.

Abstract: The present invention provides compositions and methods for inhibiting cell migration, e.g., lymphocytes and inflammation. The invention also provides an improved process for preparing fluorinated N-acetylglucosamines.

Abstract: This invention pertains to therapeutic antibacterial/antifungal-wound healing compositions comprising a therapeutically effective amount of antibacterial agents and/or antifungal agents and/or wound healing composition alone. In one embodiment, the wound healing composition comprises (a) zinc oxide; (b) calcium channel blocker, and (c) fat-soluble vitamins admixed with antibacterial and antifungal agents. The therapeutic antibacterial/antifungal-wound healing compositions may be utilized in a wide variety of pharmaceutical products and administered orally or topically.

Abstract: The inventions relates to the use of silica in the formulation of antifungal composition for the treatment of cutaneous mycoses, and method to manufacture an antifungal powder with boric acid and silica.

Abstract: The present application describes methods of using a combination of 1-(3?-aminobenzisoxazol-5?-yl)-3-trifluoromethyl-5-[[4-[(2?-dimethylaminomethyl)imidazol-1?-yl]-2-fluorophenyl]aminocarbonyl]pyrazole-hydrochloric acid salt, a factor Xa inhibitor, and Clopidogrel as anticoagulant agents for treatment of thromboembolic disorders and pharmaceutical compositions containing the same.

Abstract: Disclosed are several preferred embodiments of hydrogen peroxide which are packaged with ease of use and extended shelf-life in mind. The embodiments include foam, mist, gel, and disposable towelette forms of H2O2. Optional ingredients of topical pain relievers and skin protectants are also disclosed, as are their methods of use.

Abstract: Pharmaceutical compositions and kits comprising: (a) a tiotropium salt; and (b) a salmeterol salt having a solubility in water of 0.1 mg/mL or less, processes for preparing them, and their use in the treatment of respiratory complaints, asthma, and chronic obstructive pulmonary disease (COPD).

Abstract: Disclosed are anti-viral compositions containing at least one zinc compound and at least one phenolic antioxidant (and optionally other ingredients), and a pharmaceutical carrier. Also disclosed are methods of treating lesionous symptoms of a viral infection involving applying an effective amount of the anti-viral composition to the lesions.

Abstract: Pharmaceutical uses of glycine betaine, such as for the treatment of thromboses not induced by hyperhomocystenemia or homocystinuria, of blood disorders, such as blood coagulation, thrombi formation.

Abstract: Methods and topical pharmaceutical formulations are provided for the treatment of nail fungus (onychomycosis). The invention involves a pharmacologically active antifungal agent, plus a pharmaceutically acceptable base in a formulation having a pH of 7.5 to about 13.0, preferably about 8.0 to 11.5, and most preferably about 8.5 to 10.5. These basic formulations permeate the nail and are effective in treating fungal infections of the nail and surrounding tissues.

Abstract: A composition for accelerating the disposal of ethanol from bodily fluid. Certain additives can accelerate the metabolic oxidation of ethanol, and others in addition act as catalysts or “pseudo” enzymes for the oxidation. Additives include the oxidant Nicotinamide Adenine Dinucleotide and a variety of other additives such as transition metal ions and complexes thereof which favor the oxidation reaction. The compositions described can act as a sobriety inducer and/or as an effective palliative for the unpleasant effects of overuse of ethanol.

Abstract: A nutritional supplement to be incorporated into the diet of an individual under stress (e.g., chronic stress) is described, comprising a low-glycemic-index carbohydrate, alpha lactalbumin-enriched whey protein, fat, caffeine and a source of 5-hydroxytryptophan (5-HTP). The supplement provides active food-grade ingredients to improve the management of stress and symptoms associated therewith.

Abstract: The present invention is directed to the novel use of a CSBP/p38 inhibitor for the treatment, including prophylaxis of smoke induced pathology resulting from acute and chronic inflammation in the lung.

Abstract: One aspect of the invention relates to anti-viral composition containing at least one zinc compound and at least one phenolic antioxidant (and optionally other ingredients such as at least one analgesic) at least one hydrocarbyl containing compound, and water. Another aspect of the invention relates to a method of treating lesionous symptoms of a viral infection involving applying an effective amount of the zinc containing anti-viral composition to the lesions.

Abstract: Novel acetyloxymethyl esters are disclosed. Methods of treating an illness, including cancer, hemological disorders and inherited metabolic disorders, and treating or ameliorating other conditions using these compounds are also disclosed. The compounds are effective in the inhibition of histone deacetylase.

Abstract: The present invention provides pharmaceutical uses of betaines, and especially glycine betaine, such as for the treatment of thromboses not induced by hyperhomocystenemia or homocystinuria, of blood disorders, such as blood coagulation and thrombi formation.

Abstract: The present invention relates to the use of substrates of an UDP-glucuronosyltransferase (UGT) and salts thereof, for the prevention and/or the treatment of neurological disorders. In preferred embodiment, the present invention relates to the use of substrates of at least an UDP-glucuronosyltransferase (UGT) expressed in brain and salts thereof, for the prevention and/or the treatment of neurological disorders. It further relates to the use of said substrates, and salts thereof, for preventing and/or treating glutamate cytotoxicity, and more specifically of glutamate induced neurological disorders. Additionally, it concerns the use of said substrates, and salts thereof, for making drugs exerting an inhibitory effect on the release of glutamate.

Abstract: The invention relates to compositions and methods for treating and/or preventing lower gastrointestinal (GI) disorders in mammalian patients, more particularly for alleviating and/or preventing the lower GI symptoms associated with such disorders.

Abstract: The invention relates to compositions and methods for treating and/or preventing lower gastrointestinal (GI) disorders in mammalian patients, more particularly for alleviating and/or preventing the lower GI symptoms associated with such disorders.

Abstract: Methods and topical pharmaceutical formulations are provided for the treatment of nail fungus (onychomycosis). The invention involves a pharmacologically active antifungal agent, plus a pharmaceutically acceptable base in a formulation having a pH of 7.5 to about 13.0, preferably about 8.0 to 11.5, and most preferably about 8.5 to 10.5. These basic formulations permeate the nail and are effective in treating fungal infections of the nail and surrounding tissues.

Abstract: The present invention is a novel combination effective for alleviating pain comprising a pain alleviating effective amount of an endothelin receptor antagonist or a pharmaceutically acceptable salt thereof and from 1 to 3 compounds independently selected from the group consisting of antiepileptic compounds having pain alleviating properties and analgesics, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising same. The administration of endothelin receptor antagonists in these novel combinations results in an improved reduction in the frequency and severity of pain. The incidence of unwanted side effects can be reduced by these novel combinations in comparison to using higher doses of a single agent treatment to achieve a similar therapeutic effect. The present invention is also directed to methods of using effective amounts of the novel combinations and pharmaceutical compositions thereof to treat pain in mammals, including a human.

Abstract: Compositions for reducing an adverse skin reaction caused by a skin-irritating agent or skin sensitizing agent by treatment with a disaccharide and a metal ion, as well as methods for reducing an adverse skin reaction caused by a skin-irritating or skin-sensitizing agent, and methods for treating an inflammatory response to at least one inflammatory agent, by application of a disaccharide and/or metal ion composition.

Abstract: This invention relates to a method and compositions for the treatment and prevention of disorders associated with endothelial dysfunction consisting of anti-inflammatory agents and dietary supplements.

Abstract: The present invention provide methods and compositions for the prophylactic, targeted prophylactic, acute or acutely targeted, or subacute treatment of migraine. Representative methods include an embodiment where a patient is regularly given a therapeutically effective amount of a cyclooxygenase-2 inhibitor, an embodiment where a patient is co-administered a therapeutically effective amount of a combination of a cyclooxygenase-2 inhibitor and acetylsalicylic acid and an embodiment where a patient is co-administered a therapeutically effective amount of a combination of at cyclooxygenase-2 inhibitor and a 5-HT agonist. Representative compositions; include cyclooxygenase-2 inhibitors, HT-5 agonists, acetylsalicylic acid and combinations thereof.

Abstract: A method for the prevention, treatment, or amelioration of pain, inflammation, or inflammation-related disorder in a subject that is in need of such prevention, treatment or amelioration, involves the administration to the subject of a cyclooxygenase-2 selective inhibitor or prodrug thereof and enteric coated aspirin. A method can also involve the administration of a cyclooxygenase-2 selective inhibitor and aspirin in an amount lower than 75 mg/day. A method can also involve the administration of a cyclooxygenase-2 selective inhibitor and aspirin where the cycloxygenase-2 selective inhibitor is BMS-347070, S-33516, CS-502, darbufelone, LAS 34475, LAS 34556, L-745337, SD-8381, RWJ-63556, L-784512, COX-189, ABT-963, or valdecoxib, or any pharmaceutical salt or prodrug thereof. Compositions, pharmaceutical compositions and kits that can be used with the methods are also described.

Abstract: Composition and formulations comprising a first agent such as folinic acid, pharmaceutically acceptable salts thereof or mixtures thereof, and a second agent(s) such as analgesics, muscle relaxants, mood disorder agents, anti-inflammatories, anti-migraine agents, anti-emetics, diuretics, high protein composites, and the like. The products are suitable as nociceptics and for the treatment of wasting disorders, bulimia, anorexia nervosa, anxiety, irritability and other symptoms associated with Pre Menstrual Syndrome, as well as for administration either in conjunction with steroids or to compensate adenosine depletion and/or bizarre behavior or aggression common in steroid users.

Abstract: A pharmaceutical composition comprising an opioid agonist analgesic and an &agr;3&bgr;4 nicotinic receptor antagonist effective to separate the brain-derived wanting of the opioid from the analgesic or anti-diarrhea effect of the opioid agonist.

Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, antiinflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally.

Abstract: The present invention relates to compositions for controlled release of a cortisol antagonist comprising at least one release rate controlling substance together with said cortisol antagonist and methods of preventing or treating metabolic syndrome, diabetes mellitis type II or symptoms or complications thereof in a mammal, which method comprises administering such a composition to said mammal in an amount effective to treat one or more of the clinical manifestations of metabolic syndrome or diabetes mellitis type II as well as complications thereof.

Abstract: The present invention provides methods for preventing and treating loss of, or impairments to, the sense of balance. Specifically, the invention provides methods for preserving the sensory hair cells and neurons of the inner ear vestibular apparatus by preventing or reducing the damaging effects of oxidative stress by administering an effective amount of the following therapeutic agents: antioxidants; compounds utilized by inner ear cells for synthesis of glutathione; antioxidant enzyme inducers; trophic factors; mitochondrial biogenesis factors; and combinations thereof.

Abstract: A method is provided for inhibiting cellular uptake of cystine with a N-heterocyclic substituted salicylate for treatment such as sulfasalazine: Also provided we uses of a N-heterocyclic substituted Salicylate of cancer, for inhibition of cellular uptake of cystine, and for preparation of medicaments for the treatment of cancer or for inhibiting the cellular uptake of cystine. Preferably, the cancer is one which is dependent upon extracellular cystine or cysteine. Also provided are liposomal formulations of N-heterocyclic substituted salicylates.

Abstract: The present invention discloses a method of eliciting an analgesic effect in a subject in need thereof comprising intrathecally administering to the subject a therapeutically effective amount of a cyclooxygenase 1 inhibitor or pharmaceutically acceptable salt thereof in a preservative-free pharmaceutically acceptable carrier. The present invention further discloses pharmaceutical compositions comprising a cylcooxygenase 1 inhibitor or a pharmaceutically acceptable salt thereof and an adjuvant such as an adrenergic agonist, opioid analgesic, local anesthetic, and calcium channel blocker, and combinations thereof in a preservative-free pharmaceutically acceptable carrier. Kits comprising a composition comprising a cyclooxygenase 1 inhibitor or a pharmaceutically acceptable salt thereof in a preservative-free pharmaceutically acceptable carrier in a container suitable for delivery of the composition into an intrathecal administration device are also disclosed herein.

Abstract: Peptides and peptide compositions are identified which inhibit the growth of abnormal cells. In one embodiment, the peptides are useful for inhibiting the growth of cells dependent on autocrine activation of the PDGF receptor. Such peptides may be used in the treatment of cell proliferative disorders including cancer, fibrotic disorders, myeloproliferative diseases and blood vessel proliferative (angiogenic) disorders characterized by inappropriate PDGF receptor activity. A biomedical device is further disclosed which has associated with it a peptide or peptide composition according to the present invention.

Abstract: The present invention relates generally to mitochondria protecting agents for treating diseases in which mitochondrial dysfunction leads to tissue degeneration and, more specifically, to compounds, compositions and methods related to the same. The methods of this invention involve administration of a pharmaceutically effective amount of a mitochondria protecting agent to a warm-blooded animal in need thereof, and composition of this invention contain a mitochondria protecting agent in combination with a pharmaceutically acceptable carrier or diluent. Mitochondrial associated diseases that may be treated by the present invention include (but are not limited to) Alzheimer's Disease, diabetes mellitus, Parkinson's Disease, neuronal and cardiac ischemia, Huntington's disease and stroke.

Abstract: The present invention provides compositions and methods for inhibiting cell migration, e.g., lymphocytes and inflammation. The invention also provides an improved process for preparing fluorinated N-acetylglucosamines.

Abstract: A pharmaceutical composition comprises one or more discrete orally deliverable dosage forms, each comprising a poorly soluble coxib component in an amount effective when administered once daily for treatment or prevention of a COX-2 mediated disorder, an aspirin component in a cardioprotective effective amount when administered once daily, and at least one pharmaceutically acceptable excipient; the dosage forms having no substantial barrier to intimate commingling of the coxib and aspirin components. A method of simultaneously treating or preventing a COX-2 mediated disorder and providing cardioprotection comprises orally administering such a pharmaceutical composition to a subject in need thereof.

Abstract: A composition which includes a purine, an NSAID, and a pharmaceutical excipient and/or vehicle. A method which treats male or female sexual dysfunction and includes administering a therapeutically effective amount of the composition to a person. A method which prevents male or female sexual dysfunction and includes administering a therapeutically effective amount of the composition to a person, and a method for increasing sexual desire and/or promoting sexual activity and/or increasing sexual capacities and/or promoting sexual activity and/or improving the intensity of sexual pleasure and/or promoting the attainment of satisfying sexual relations in persons not suffering from sexual dysfunctions and includes administering to a person a composition including a purine and an NSAID.

Abstract: A method which treats inflammation or thrombosis and includes administering to a mammal a therapeutically effective amount of a composition including a purine and an NSAID as active ingredients. A method which prevents inflammation or thrombosis and includes administering to a mammal a therapeutically effective amount of a composition including a purine and an NSAID as active ingredients. An anti-inflammatory or anti-thrombotic composition which includes one or more molecules of purine covalentlylinked to one or more molecules of NSAID, or optionally, by at least one spacer arm intermediary.

Abstract: The present invention is directed to novel pharmaceutical combinations including compositions and kits comprising bretylium as the active ingredient, as well as methods for preventing and/or treating conditions related to the cardiovascular system using such novel pharmaceutical combinations.

Abstract: Compositions including a quinolone component in an amount effective as an antibiotic when the composition is placed in a mammalian eye, and a carrier component in an amount effective to act as a carrier for the quinolone component are provided. The present compositions are substantially free of other components effective as preservatives. Preferably the quinolone component has fungistatic activity. In one very useful embodiment, the compositions include a NSAID component in an amount effective to reduce inflammation or pain when the composition is placed in a mammalian eye. Methods of using the present compositions, for example, to resolve microbial infections and/or to reduce inflammation and/or pain in a mammalian eye are included within the scope of the present invention.

Abstract: The invention relates to the use of an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of acute MI and for the secondary prevention of acute MI.

Abstract: This invention provides for the treatment of inflammatory, cancer and thrombotic disorders through the administration, in combination, of a COX2 inhibitor, low dose aspirin, and antioxidant flavanoids, flavonoids or isoflavones and at least one of these combinations will be given in a subtherapeutic amount for improved anti-inflammatory, anti-cancer, and anti-thrombotic efficacy and safety.

Abstract: The invention provides a method of treating or preventing rosacea, comprising topical administration, of a pharmaceutical preparation comprising a nonsteroidal anti-inflammatory drug (NSAID).

Abstract: The present invention provides novel pharmaceutical combinations and their use in anti-thrombotic therapy.

Abstract: The invention provides a method for treating, preventing, or reducing the risk of developing a condition selected from the group consisting of acute coronary ischemic syndrome, thrombosis, thromboembolism, thrombotic occlusion and reocclusion, restenosis, transient ischemic attack, and first or subsequent thrombotic stroke, in a patient, comprising administering to the patient a therapeutically effective amount of an antiplatelet agent in combination with a therapeutically effective amount of a COX-2 inhibitor. The invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a COX-2 inhibitor, or a pharmaceutically acceptable salt thereof, and an antiplatelet agent, or a pharmaceutically acceptable salt thereof.

Abstract: A synergistic combination of pravastatin and aspirin is provided which is formed of 40 mg pravastatin and 81 mg or higher of aspirin, preferably 81 mg aspirin or 325 mg of aspirin. A method for preventing, inhibiting or reducing risk of onset of cardiovascular events or cerebrovascular events employing such synergistic combination is also provided.